Kooijmans et al. [97] introduced anti-epidermal growth factor receptor (EGFR) nanobodies with glycosylphosphatidylinositol (GPI) anchor signal peptides derived from decay-accelerating factor (DAF) fusion expression vectors into EVs-producing cells and successfully targeted tumor cells. The gene discussed is EGFR; the disease is neoplasm.